A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris

Protein Expression and Purification

Volumn 119, Issue , 2016, Pages 1-10

  Cerini, Fabrice ^a   Gaertner, Hubert ^a   Madden, Knut ^b   Tolstorukov, Ilya ^b,c   Brown, Scott ^d   Laukens, Bram ^e   Callewaert, Nico ^e   Harner, Jay C ^f   Oommen, Anna M ^f   Harms, John T ^f   Sump, Anthony R ^f   Sealock, Robert C ^f   Peterson, Dustin J ^f   Johnson, Scott K ^f   Abramson, Stephan B ^g   Meagher, Michael ^f   Offord, Robin ^h   Hartley, Oliver ^a,h  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Biogrammatics Inc   (United States)

^c KECK GRADUATE INSTITUTE   (United States)

^d Biologies Process Development   (United States)

^e GHENT UNIVERSITY   (Belgium)

^f UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^g LifeSci Partners   (United States)

^h Mintaka Foundation for Medical Research   (Switzerland)

Author keywords

5P12 RANTES; Biopharmaceutical; CCR5; cGMP; Chemokine; HIV; Microbicide; Pichia; Process development; Yeast

Indexed keywords

5P12-RANTES; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA CHEMOKINE;

BIOREACTOR; BIOSYNTHESIS; DRUG EFFECTS; ECONOMICS; FERMENTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IC50; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; PICHIA; PILOT STUDY; STANDARDS; VIRUS ENTRY;

ANTI-HIV AGENTS; BIOREACTORS; CHEMOKINES, CC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; FERMENTATION; HIV; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; PICHIA; PILOT PROJECTS; VIRUS INTERNALIZATION;

EID: 84947254815     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2015.10.011     Document Type: Article

References (39)

1. UNAIDS Global Report: UNAIDS Report on the Global AIDS Epidemic, 2013 2013 Geneva
2. R.J. Shattock, and Z. Rosenberg Microbicides: topical prevention against HIV Cold Spring Harb. Perspect. Med. 2 2012 a007385
3. M.M. Lederman, A. Penn-Nicholson, M. Cho, and D. Mosier Biology of CCR5 and its role in HIV infection and treatment JAMA 296 2006 815 826
4. M.M. Lederman, R.E. Offord, and O. Hartley Microbicides and other topical strategies to prevent vaginal transmission of HIV Nat. Rev. Immunol. 6 2006 371 382
5. M.M. Lederman, R.S. Veazey, R. Offord, D.E. Mosier, J. Dufour, M. Mefford, M. Piatak Jr., J.D. Lifson, J.R. Salkowitz, B. Rodriguez, A. Blauvelt, and O. Hartley Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 Science 306 2004 485 487
6. O. Hartley, and R.E. Offord Engineering chemokines to develop optimized HIV inhibitors Curr. Protein Pept. Sci. 6 2005 207 219
7. H. Gaertner, F. Cerini, J.M. Escola, G. Kuenzi, A. Melotti, R. Offord, I. Rossitto-Borlat, R. Nedellec, J. Salkowitz, G. Gorochov, D. Mosier, and O. Hartley Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide Proc. Natl. Acad. Sci. U. S. A. 105 2008 17706 17711
8. O. Hartley, H. Gaertner, J. Wilken, D. Thompson, R. Fish, A. Ramos, C. Pastore, B. Dufour, F. Cerini, A. Melotti, N. Heveker, L. Picard, M. Alizon, D. Mosier, S. Kent, and R. Offord Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors Proc. Natl. Acad. Sci. U. S. A. 101 2004 16460 16465
9. J.P. Moore Topical microbicides become topical N. Engl. J. Med. 352 2005 298 300
10. O. Hartley, K. Dorgham, D. Perez-Bercoff, F. Cerini, A. Heimann, H. Gaertner, R.E. Offord, G. Pancino, P. Debre, and G. Gorochov Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines J. Virol. 77 2003 6637 6644
11. R.S. Veazey, B. Ling, L.C. Green, E.P. Ribka, J.D. Lifson, M. Piatak Jr., M.M. Lederman, D. Mosier, R. Offord, and O. Hartley Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge J. Infect. Dis. 199 2009 1525 1527
12. F. Cerini, A. Landay, C. Gichinga, M.M. Lederman, R. Flyckt, D. Starks, R.E. Offord, F. Le Gal, and O. Hartley Chemokine analogues show suitable stability for development as microbicides J. Acquir Immune Defic. Syndr. 49 2008 472 476
13. R. Nedellec, M. Coetzer, M.M. Lederman, R.E. Offord, O. Hartley, and D.E. Mosier Resistance to the CCR5 Inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use PLoS ONE 6 2011 e22020
14. S. Masure, L. Paemen, P. Proost, J.O. Van Damme, and G. Opdenakker Expression of a human mutant monocyte chemotactic protein 3 in Pichia Pastoris and characterization as an MCP-3 receptor antagonist J. Interferon Cytokine Res. 15 1995 955 963
15. Y. Maeda, R. Kuroki, H. Suzuki, and H. Reiländer High-level secretion of biologically active recombinant human macrophage inflammatory protein-1α by the methylotrophic yeast Pichia Pastoris Protein Expr. Purif. 18 2000 56 63
16. H. Li, D. Wang, A. Xu, S. Li, S. Jin, and D. Wu High level expression and purification of active recombinant human interleukin-8 in Pichia pastoris Protein Expr. Purif. 68 2009 60 64
17. L.G. Czaplewski, J. McKeating, C.J. Craven, L.D. Higgins, V. Appay, A. Brown, T. Dudgeon, L.A. Howard, T. Meyers, J. Owen, S.R. Palan, P. Tan, G. Wilson, N.R. Woods, C.M. Heyworth, B.I. Lord, D. Brotherton, R. Christison, S. Craig, S. Cribbes, R.M. Edwards, S.J. Evans, R. Gilbert, P. Morgan, M.G. Hunter, and et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants J. Biol. Chem. 274 1999 16077 16084
18. V. Appay, A. Brown, S. Cribbes, E. Randle, and L.G. Czaplewski Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants J. Biol. Chem. 274 1999 27505 27512
19. C.P. Kurtzman Biotechnological strains of Komagataella (Pichia) pastoris are Komagataella phaffii as determined from multigene sequence analysis J. Ind. Microbiol. Biotechnol. 36 2009 1435 1438
20. M. Schnolzer, P. Alewood, A. Jones, D. Alewood, and S.B. Kent In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences Int. J. peptide protein Res. 40 1992 180 193
21. J. Wilken, D. Hoover, D.A. Thompson, P.N. Barlow, H. McSparron, L. Picard, A. Wlodawer, J. Lubkowski, and S.B. Kent Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES Chem. Biol. 6 1999 43 51
22. J.M. Cregg, I. Tolstorukov, A. Kusari, J. Sunga, K. Madden, and T. Chappell Expression in the yeast Pichia pastoris Methods Enzymol. 463 2009 169 189
23. L.W. Dick Jr., C. Kim, D. Qiu, and K.C. Cheng Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides Biotechnol. Bioeng. 97 2007 544 553
24. F.S. Hartner, and A. Glieder Regulation of methanol utilisation pathway genes in yeasts Microb. Cell Fact. 5 2006 39
25. P.J. Klasse, R. Shattock, and J.P. Moore Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission Annu. Rev. Med. 59 2008 455 471
26. R.S. Veazey, P.J. Klasse, S.M. Schader, Q. Hu, T.J. Ketas, M. Lu, P.A. Marx, J. Dufour, R.J. Colonno, R.J. Shattock, M.S. Springer, and J.P. Moore Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion Nature 438 2005 99 102
27. R.S. Veazey, T.A. Ketas, P.J. Klasse, D.K. Davison, M. Singletary, L.C. Green, M.L. Greenberg, and J.P. Moore Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249 Proc. Natl. Acad. Sci. U. S. A. 105 2008 10531 10536
28. R.S. Veazey, T.J. Ketas, J. Dufour, T. Moroney-Rasmussen, L.C. Green, P.J. Klasse, and J.P. Moore Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor J. Infect. Dis. 202 2010 739 744
29. L. Myer, C. Mathews, and F. Little Condom use and sexual behaviors among individuals procuring free male condoms in South Africa: a prospective study Sex. Transm. Dis. 29 2002 239 241
30. M. Ahmad, M. Hirz, H. Pichler, and H. Schwab Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production Appl. Microbiol. Biotechnol. 98 2014 5301 5317
31. S.C. Spohner, H. Muller, H. Quitmann, and P. Czermak Expression of enzymes for the usage in food and feed industry with Pichia pastoris J. Biotechnol. 202 2015 118 134
32. R. Aw, and K.M. Polizzi Can too many copies spoil the broth? Microb. Cell Fact. 12 2013 128
33. M. Guerfal, S. Ryckaert, P.P. Jacobs, P. Ameloot, K. Van Craenenbroeck, R. Derycke, and N. Callewaert The HAC1 gene from Pichia pastoris: characterization and effect of its overexpression on the production of secreted, surface displayed and membrane proteins Microb. Cell Fact. 9 2010 49
34. C. Sha, X.W. Yu, N.X. Lin, M. Zhang, and Y. Xu Enhancement of lipase r27RCL production in Pichia pastoris by regulating gene dosage and co-expression with chaperone protein disulfide isomerase Enzyme Microb. Technol. 53 2013 438 443
35. G.C. Morris, R.C. Wiggins, S.C. Woodhall, J.M. Bland, C.R. Taylor, V. Jespers, B.A. Vcelar, and C.J. Lacey MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide PLoS ONE 9 2014 e116153
36. J.L. Fuqua, V. Wanga, and K.E. Palmer Improving the large scale purification of the HIV microbicide, griffithsin BMC Biotechnol. 15 2015 12
37. M. Niemer, U. Mehofer, J.A. Torres Acosta, M. Verdianz, T. Henkel, A. Loos, R. Strasser, D. Maresch, T. Rademacher, H. Steinkellner, and L. Mach The human anti-HIV antibodies 2F5, 2G12, and PG9 differ in their susceptibility to proteolytic degradation: down-regulation of endogenous serine and cysteine proteinase activities could improve antibody production in plant-based expression platforms Biotechnol. J. 9 2014 493 500
38. B.R. O'Keefe, A.M. Murad, G.R. Vianna, K. Ramessar, C.J. Saucedo, J. Wilson, K.W. Buckheit, N.B. da Cunha, A.C. Araujo, C.C. Lacorte, L. Madeira, J.B. McMahon, and E.L. Rech Engineering soya bean seeds as a scalable platform to produce cyanovirin-N, a non-ARV microbicide against HIV Plant Biotechnol. J. 13 2015 884 892
39. W.H. Assembly Access to Biotherapeutic Products Including Similar Biotherapeutic Products and Ensuring Their Quality, Safety and Efficacy 2014 World Health Organisation